Detect cancer when it matters
the most—Because everyone
deserves a fighting chance.
The key to managing cancer is early detection. ClearNote Health makes this possible by finding signals of cancer in your blood early, when treatment is the most effective.
ClearNote Health’s proprietary epigenomic platform and cell-free DNA-based assays measure dynamic biological changes in cells to provide an early signal of a developing cancer.
ClearNote Health focuses on cancers with high mortality rates for which there are no or very limited detection options.
We are proud of the clinical evidence, R&D achievements, and our five-year-long company development as Bluestar Genomics. Now, as a commercial-stage company, ClearNote Health continues to drive innovation in non-invasive cancer detection, with patient needs at the core of everything we pursue.
January 9, 2023
ClearNote Health to Present at 41st Annual J.P. Morgan Healthcare Conference
December 21, 2022
CEO Perspective: We are ClearNote Health – Allow Us to Re-Introduce Ourselves